白细胞介素-6水平与三阴性乳腺癌新辅助化疗效果的相关性

doi:10.3969/j.issn.1671-7171.2021.08.021

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1168 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨白细胞介素-6 (IL-6)水平与三阴性乳腺癌新辅助化疗效果的相关性。【方法】在本院行术前新辅助化疗的局部晚期乳腺浸润性导管癌患者120例,免疫组化结果均为三阴性乳腺癌。检测患者新辅助化疗前外周血IL-6水平,分析IL-6水平与患者临床病理因素的相关性,并分析其与化疗效果、病理完全缓解(pCR)的相关性。【结果】IL-6水平为(119.8±20.8)pg/mL,根据IL-6水平中位数(118 pg/mL)将患者分为IL-6低水平组(60例)和IL-6高水平组(60例)。IL-6水平与三阴性乳腺癌年龄、绝经状态、肿瘤大小、肿瘤最长经无相关性(P>0.05),IL-6水平与三阴性乳腺癌临床分期、淋巴结状态具有相关性(P<0.05)。IL-6高水平组患者CR率,总有效率低于IL-6低水平组,且差异有显著性(P<0.05)。共25例患者术后达pCR,pCR与临床分期、IL-6水平、肿瘤最长径具有相关性(P<0.05)。多因素回归分析显示,临床分期、IL-6水平是pCR独立影响因素。【结论】IL-6水平与三阴性乳腺癌新辅助化疗疗效相关,IL-6高水平的三阴性乳腺癌患者pCR率较低。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：乳腺肿瘤/药物疗法, 白细胞介素6, 受体,erbB-2, 雌激素类, 孕酮, 化学疗法,辅助

Abstract：【Objective】To investigate the correlation between IL-6 levels and neoadjuvant chemotherapy for triple-negative breast cancer. 【Methods】A total of 120 patients with locally advanced breast invasive ductal carcinoma who underwent preoperative neoadjuvant chemotherapy in our hospital. The immunohistochemical results were all triple negative breast cancer. The level of IL-6 in peripheral blood before neoadjuvant chemotherapy was measured, and the correlation between IL-6 level and clinicopathological factors was analyzed. The correlation between chemotherapy and pathological complete remission (pCR) was analyzed. 【Results】The IL-6 level was (119.8±20.8) pg/mL. According to the median IL-6 level (118 pg/ml), the patients were divided into IL-6 low level group (60 cases) and IL-6 high level group (60 cases). There was no correlation of IL-6 level with age, menopausal status, tumor size and clinical stage in triple-negative breast cancer patients (P>0.05). IL-6 level was correlation with clinical stage and lymph node status of triple-negative breast cancer, the difference was statistically significant(P<0.05). The CR rate in the IL-6 high-level group was lower than that in the IL-6 low-level group, and the effective rate was lower than the IL-6 low-level group , the difference was statistically significant (P<0.05). A total of 25 patients had pCR after operation, and pCR was associated with clinical stage, IL-6 level, and tumor longest interval (P<0.05). Multivariate regression analysis showed clinical stage, IL-6 levels were independent factors affecting pCR. 【Conclusion】The level of IL-6 is associated with the efficacy of neoadjuvant chemotherapy for triple-negative breast cancer. The high-level IL-6 level of triple-negative breast cancer patients has a lower pCR rate.

Key words： Breast Neoplasms/DT Interleukin-6 Receptor, ErbB-2 Estrogens Progesterone Chemotherapy, Adjuvant

收稿日期: 2019-10-10

中图分类号:

R737.9

通讯作者: * E-mail:Yanguilai410@163.com

引用本文:

于金雨, 刘大林, 王岐朋, 张建波, 南云广, 刘敬西. 白细胞介素-6水平与三阴性乳腺癌新辅助化疗效果的相关性[J]. 医学临床研究, 2021, 38(8): 1191-1193.
YU Jin-yu, LIU Da-lin, WANG Qi-peng, et al. Correlation between IL-6 Level and Neoadjuvant Chemotherapy in Triple-negative Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(8): 1191-1193.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.08.021 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I8/1191